Disease - International Biopharmaceutical Industry

news

Scientists home in on cause of Duchenne gene therapy side effect

Duchenne muscular dystrophy, a degenerative disease mostly affecting young boys, is one of the top targets for gene therapy developers. Recently, however, the pace of...

22 May 2022 news Disease | Duchenne

Continue Reading →

news

Biogen CEO to step down as company pulls back from Alzheimer’s drug

Biogen is searching for a new CEO along with additional ways to cut costs after another quarter of paltry sales for its closely watched Alzheimer’s disease drug. Onc...

9 May 2022 news Alzheimer | Biogen

Continue Reading →

news

FDA advisers narrowly side against an experimental ALS drug, likely lowering its approval chances

By a slim margin, advisers to the Food and Drug Administration have concluded that the agency should hold off approving a closely watched, experimental medicine for A...

1 April 2022 news ALS | Amylyx

Continue Reading →

news

With trial success in kidney disease, Lilly, Boehringer make case for broader use of diabetes drug

Dive Brief: Eli Lilly and Boehringer Ingelheim's drug Jardiance kept clinical trial participants with kidney disease from needing dialysis or a transplant, the com...

21 March 2022 news Boehringer | diabetes

Continue Reading →

news

Roche revives a closely watched Huntington’s disease drug

Dive Brief: Roche has outlined a new clinical path forward for a closely watched Huntington's disease drug ten months after disappointing Phase 3 study results app...

20 January 2022 news Disease | Huntington

Continue Reading →

news

Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird’s crucial year

The biggest industry news of the week came not from the J.P. Morgan Healthcare Conference or any associated announcements, but from Washington, D.C, where the Centers...

14 January 2022 news Alzheimer | blood

Continue Reading →

news

Novartis hits another setback in plan to repurpose rare disease drug in lung cancer

Novartis' testing of canakinumab, which works by curbing inflammatory signaling in cells, for the seemingly unrelated use in lung cancer stems from an intriguing 2011...

29 October 2021 news cancer | cells

Continue Reading →

Volume 4 Issue 3

Shoring up Diagnostics Manufacturing for the Next Pandemic

As the global response to COVID-19 continues to move from a state of national lockdowns to the re-opening of societies, diagnostic assay developers are confronting tw...

1 September 2021 Volume 4 Issue 3 COVID-19 | Disease

Continue Reading →

Current Edition

Upcoming Events

Advertisement

Scientists home in on cause of Duchenne gene therapy side effect

Biogen CEO to step down as company pulls back from Alzheimer’s drug

FDA advisers narrowly side against an experimental ALS drug, likely lowering its approval chances

With trial success in kidney disease, Lilly, Boehringer make case for broader use of diabetes drug

Roche revives a closely watched Huntington’s disease drug

Aftershocks for Lilly, CRISPR versus CRISPR and Bluebird’s crucial year

Novartis hits another setback in plan to repurpose rare disease drug in lung cancer

Shoring up Diagnostics Manufacturing for the Next Pandemic

International Biopharmaceutical Industry